## min read

MTHFR Gene Mutation: What It Means for Mental Health

|

October 17, 2026

Summarize with AI

MTHFR Gene Mutation: What It Means for Mental Health

Maybe a genetic report flagged it. Maybe a friend, a forum, or a supplement ad told you it could explain your fatigue, your depression, or why medication never quite worked. Now you're wondering what an MTHFR gene mutation actually means for you.

MTHFR variants are extremely common. Most people who carry them have no health effects at all, and research linking them to mental health conditions shows a real but small association, not a cause. Medical experts don't recommend routine testing for them.

What the MTHFR gene does

The MTHFR gene carries instructions for an enzyme called methylenetetrahydrofolate reductase. That enzyme converts folate, a B vitamin, into the active form your body uses to turn the amino acid homocysteine into methionine. According to MedlinePlus Genetics, the active form, 5-methyltetrahydrofolate, is the main form of folate found in blood.

When the enzyme works less efficiently, homocysteine can build up. That's the mechanism behind most of the interest in MTHFR, including the mental health questions.

C677T, A1298C, heterozygous, and homozygous

Most people searching "MTHFR gene mutation" are really asking about two common variants:

  • C677T. The most common and best studied. At position 677 in the gene, the DNA base C is replaced by T. The resulting enzyme is less stable and less active, especially in people with two copies.
  • A1298C. The second common variant. The CDC notes there isn't enough evidence that A1298C on its own significantly affects how the body processes folate.

You inherit one copy of the gene from each parent, which is where the lab terms come from:

  • Heterozygous means one copy carries the variant (for C677T, written CT).
  • Homozygous means both copies carry it (TT).
  • Compound heterozygous means one copy of C677T and one copy of A1298C.

These variants are so common they're closer to normal human variation than to a disease. The CDC reports that more people in the U.S. have one or two copies of C677T than don't. Having both copies is less common: MedlinePlus estimates about 25% of Hispanic people and 10% to 15% of North American white people carry two copies of C677T.

MTHFR symptoms: what the variant does and doesn't cause

Most people with common MTHFR variants have no symptoms. Cleveland Clinic puts it plainly: MTHFR gene variants most often don't affect your health or cause symptoms. When they do matter, it's usually through higher homocysteine or lower folate, and mostly in people with two copies of C677T. Even then, how much folate you get from food matters more than your genotype.

That's different from what you'll read on many wellness sites, which attribute everything from fatigue to brain fog to MTHFR. There's no reliable evidence for a list of "MTHFR symptoms" in people with the common variants. If you have symptoms, they deserve an evaluation, not an assumption that a gene variant explains them.

There is one important exception. Rare, severe mutations in the MTHFR gene cause homocystinuria, a serious inherited condition whose symptoms usually appear early in life. Most U.S. newborns are screened for it shortly after birth. That's a different situation from the common C677T and A1298C variants.

MTHFR and mental health: what research shows

Because MTHFR sits in the folate and methylation pathway, researchers have looked hard for links to psychiatric conditions. The findings are consistent in one way: the effect is modest.

  • Depression. A 2013 meta-analysis of 26 studies, with 4,992 people with depression and 17,082 controls, found that two copies of C677T were associated with higher odds of depression (odds ratio 1.42). The link was stronger in Asian populations, marginal in white populations, and absent in older adults.
  • Schizophrenia, bipolar disorder, and depression combined. A 2011 meta-analysis of case-control studies with 29,502 participants found TT carriers had modestly higher odds of these conditions as a group (odds ratio 1.26). The authors read this as evidence of a shared genetic vulnerability across the three conditions.

An odds ratio of 1.26 to 1.42 is a small increase in relative risk for a very common genotype. Most people with two copies of C677T never develop depression, bipolar disorder, or schizophrenia, and most people with those conditions don't have two copies. Mental health conditions come from many genes and life experiences acting together. MTHFR is, at most, one small piece.

Folate, folic acid, and methylfolate

A common online claim is that people with MTHFR variants can't use folic acid and need "methylated" supplements instead. The CDC says that isn't true: people with an MTHFR variant can process all types of folate, including folic acid. People with the TT genotype have blood folate levels only about 16% lower on average than people with CC at the same intake, and folic acid intake matters more than genotype in determining blood folate.

L-methylfolate, the active form, has been studied as an add-on to antidepressants. In two randomized trials published in the American Journal of Psychiatry in 2012, adults with depression that hadn't responded fully to an SSRI received L-methylfolate or placebo alongside their medication. The first trial, with 148 patients starting at 7.5 mg a day, found no difference. The second, with 75 patients at 15 mg a day, found a significant benefit over placebo. Both enrolled people based on their depression, not on a genetic test. Whether any add-on makes sense for a specific person is a clinical decision that depends on their full history.

For more on how folate and other nutrients relate to mood, see our article on nutrient deficiencies and anxiety.

Should you get tested for MTHFR?

For most people, no. MedlinePlus states that medical experts don't recommend testing for common MTHFR gene changes in most cases. A provider may order it in specific situations, such as high homocysteine on a blood test combined with a family history.

The American College of Medical Genetics and Genomics went further in a 2013 practice guideline: MTHFR polymorphism testing has minimal clinical utility and shouldn't be part of a routine evaluation for blood clotting disorders. Recent meta-analyses had disproven the links that originally motivated the testing.

If you already have a result, it's still useful context to share with your care team. It just isn't a diagnosis, and it isn't a treatment plan.

When depression or mood symptoms don't improve

People often look up MTHFR because something isn't working: depression that keeps coming back, medication that only half helps, or mood swings no one has explained. Those problems are real, even if MTHFR is unlikely to be the answer. They usually call for a fuller psychiatric evaluation: a closer look at the diagnosis, past medication trials, co-occurring conditions, sleep, substance use, and physical health.

That's the kind of care we provide at Amae Health. Our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, and schizophrenia. Our care teams bring psychiatrists, therapists, primary care physicians, and dietitians under one roof, so lab results, nutrition, and medication history are reviewed together, by people who share one treatment plan. See how our integrated outpatient clinics work.

Frequently asked questions

How common is the MTHFR gene mutation?

Very common. According to the CDC, more people in the U.S. have one or two copies of the C677T variant than don't. Two copies are less common, estimated at about 25% of Hispanic people and 10% to 15% of North American white people.

What are the symptoms of being MTHFR C677T heterozygous?

Usually none. According to MedlinePlus, raised homocysteine is seen mainly in people with two copies of C677T. If you have symptoms, they need an evaluation of their own rather than being attributed to one copy of a common variant.

Does MTHFR cause depression?

No single gene causes depression. Two copies of C677T are associated with modestly higher odds of depression in meta-analyses, with an odds ratio around 1.4, but most people who carry them never develop depression.

Do people with MTHFR need methylfolate instead of folic acid?

According to the CDC, no. People with MTHFR variants can process folic acid, and folic acid intake matters more than genotype for blood folate levels. L-methylfolate has been studied as an add-on treatment for depression, regardless of MTHFR status, and decisions about it belong with a clinician.

Is MTHFR testing worth it?

For most people, it isn't recommended. Medical genetics experts say the common variants have minimal clinical utility. A provider may order testing in specific cases, such as unexplained high homocysteine with a family history.

Key takeaways

  • An MTHFR gene mutation usually means one or two copies of the common C677T or A1298C variants, which most people carry without health effects.
  • Two copies of C677T can raise homocysteine and are linked to modestly higher odds of depression, bipolar disorder, and schizophrenia, but the effect is small.
  • People with MTHFR variants can process folic acid, and routine MTHFR testing isn't recommended.
  • If depression or mood symptoms aren't improving, a full psychiatric evaluation is more useful than a gene result.

If you or someone you love is living with depression, bipolar disorder, or schizophrenia that hasn't responded to treatment, request an intake appointment. Our team will walk you through how an evaluation works and what to bring, including any lab or genetic results you already have.

Reccomended for you

# min read

Schizophrenia Treatment Options: Navigating the Path to Recovery

By

Sonia Garcia

|

May 15, 2026

A schizophrenia diagnosis arrives to a person in a small room, and rearranges things without asking — the way a conversation feels, the way a plan for next year suddenly needs rewriting, the way someone you love looks at you and you can't quite tell what they're thinking anymore. Most of what you'll read about schizophrenia treatment options is either clinical to the point of cold, or optimistic in a way that skips the hard parts. 

Schizophrenia is a chronic condition. In 2026, it is also named one of the most treatable severe mental illnesses in psychiatry. The medications have quietly changed over the last two years, with the care models changing even faster. And the question clinicians now ask (is this person living a life they recognize as their own?) is a better question than the one psychiatry asked a generation ago.

This is a guide to what schizophrenia treatment actually looks like now.

What "Treatment" Means for Schizophrenia in 2026

For most of psychiatry's history, treating schizophrenia meant turning down the volume on hallucinations and delusions and hoping everything else would hold. Consequently, it often didn't. The older medications were blunt instruments — they could quiet the psychosis while leaving a person sedated, emotionally flat, and unable to concentrate. A patient could be symptom-free on paper and still lose their apartment, their job, and their social world, not because the illness had won, but because the treatment had taken too much with it.

That old goal has been replaced.

The modern target is functional recovery: the ability to live a connected, productive life, be it work or school. Rebuilding the relationships that came apart during the acute phase. Living on your own terms. Functional recovery is not the same as symptom elimination. Some of the people who reach it still hear voices, and some of the people with zero symptoms can't hold a routine. What functional recovery actually requires, almost without exception, is a care plan that treats medication, therapy, physical health, and social support as one whole problem instead of four.

Pharmacological Breakthroughs: A New Era of Medication

Medication is the floor of schizophrenia treatment, not the ceiling. For about 40 years, that floor was built of one material: antipsychotics that bind dopamine D2 receptors and block the signal. That is still the starting point for most patients in 2026. What has quietly changed is the field, which now has options that were not there two years ago.

Second-Generation Antipsychotics: The Current Standard

Risperidone, olanzapine, aripiprazole, paliperidone, quetiapine. Those are the names that will likely appear first in any conversation with a psychiatrist. They're called "second-generation" or "atypical" antipsychotics because together, they work on dopamine and serotonin, producing a more favorable profile for negative symptoms and cognitive effects than the drugs that came before them.

They work. They also come at a cost.

The trade-off is metabolic. Weight gain. Elevated blood sugar. Shifts in lipid panels that, untracked, add up to real cardiovascular risk over time. A care team that prescribes these medications without monitoring the body is doing half the job. Metabolic monitoring is not optional.

The Non-Dopaminergic Revolution: Cobenfy and Muscarinic Agonists

In September 2024, something happened in schizophrenia pharmacology for the first time in about 35 years. The FDA approved xanomeline-trospium (Cobenfy, formerly known as KarXT), and the mechanism was not a variation on the dopamine theme. Cobenfy works on muscarinic receptors (specifically the M1 and M4 subtypes), meaning the biological pathway it acts on is different in kind, not just in detail (Yale Medicine).

Here is why that matters.

Roughly one-third of patients don't respond adequately to dopamine-based medications. The metabolic and movement-related side effects of the older drugs are also downstream of dopamine blockade. Cobenfy doesn't block dopamine, which is why early trials suggest it may avoid some of that side effect profile.

Long-term data is still accumulating. For now, the field has its first new mechanism in a generation.

Long-Acting Injectables: Reducing the Daily Burden

Long-acting injectable antipsychotics, or LAIs, deliver a single dose that lasts weeks or even months. For patients whose relapses have traced back to missed pills, that is a meaningful shift.

The evidence has caught up with the intuition. A 2022 network meta-analysis in World Psychiatry pooled 92 randomized trials and 22,645 participants and found that LAIs hold up against daily oral antipsychotics in preventing relapse (Ostuzzi et al., 2022). Real-world studies of US Medicare patients have shown LAIs are associated with lower rates of psychiatric hospitalization and treatment discontinuation.

LAIs are not right for every patient. Some people find meaning in the daily ritual of a pill. Some have had painful experiences with injections. The right answer comes out of a real conversation with a psychiatrist who has the patient's history in front of them.

Models of Care: Why the Environment Matters

The same medication can produce very different outcomes depending on how it is delivered. Two patients on the same dose of the same drug can end up in very different places a year later. The difference is usually the system around them.

Coordinated Specialty Care (CSC)

In 2026, coordinated Specialty Care is the standard for early psychosis.It is also one of the clearest examples in psychiatry of a care model producing better outcomes than a new drug would. The American Psychiatric Association formally endorsed it in its 2020 practice guideline (APA Practice Guideline for the Treatment of Patients With Schizophrenia), and it came out of the NIMH RAISE research initiative.

The model is a single team of clinicians working from one plan: medication management, individual therapy, supported employment and education, family education, and case management that actually happens, rather than getting sent to five different offices on five different days.

The data is strong. In the NIMH RAISE Early Treatment Program, patients who received CSC had hospitalization rates of 23% compared with 44% in usual community care (NIMH: Team-based Treatment is Better for First Episode Psychosis). They were also more likely to stay in school or employment and experienced greater improvement in symptoms, interpersonal relationships, and quality of life (Kane et al., American Journal of Psychiatry, 2016).

That is a halving of hospitalization risk, produced by a care model rather than a new molecule.

CSC was built for early psychosis. For patients further along in treatment, other models fit better.

Integrated Outpatient Care for Severe Mental Illness

For patients past the first-episode window, integrated outpatient care takes the same principle as CSC and adapts it for the long haul. The model brings psychiatrists, therapists, primary care physicians, dietitians, health coaches, peer mentors, and clinical care coordinators under one roof, working from a single shared plan.

The problem it solves is fragmentation. In the usual picture, a patient has a psychiatrist at one office, a therapist at another, a primary care provider at a third, and if case management exists at all, it runs on lost email attachments. Small things become crises. Crises become hospitalizations. Hospitalizations become the next relapse.

But it doesn't have to work that way.

This is the model our integrated outpatient clinics are built on. We see adults 18 and older. Our care team is designed so that mental health, physical health, and everyday function are handled in the same place, by people who talk to each other. The patient is not the one running the coordination.

Crisis Services and Long-Term Stability

Crisis services are not long-term care, and long-term care is not crisis services. Inpatient hospitalization exists to keep people safe when symptoms are acute. It is essential, and it saves lives. But it is not designed to produce long-term stability, and the handoff from inpatient to outpatient is the highest-risk period for readmission. That handoff is where integrated outpatient care earns its keep.

Evidence-Based Psychosocial Interventions

Medication does one job well. It quiets the biology. Everything else is outside what a pill can do: how a person thinks about what is happening to them, how they rebuild relationships that came apart during the acute phase, how they get back into work or school.

That is where psychosocial interventions come in.

Cognitive Behavioral Therapy for Psychosis (CBTp)

CBT for Psychosis, usually shortened to CBTp, is not standard CBT with a few tweaks. It is a specialized protocol built from the ground up for people who hear voices, hold persistent unusual beliefs, or are trying to function while symptoms are still present. The APA practice guideline gives CBTp a 1B rating, which translates roughly to "the evidence is strong and clinicians should offer this" (APA Practice Guideline, 2020).

What CBTp actually does in a session is teach specific skills. Reality testing. Cognitive distancing from distressing voices. Stress-reduction techniques for the moments when symptoms spike. Coping strategies for persistent delusions that have not responded fully to medication. The goal is not to eliminate the symptoms. It is to change the relationship a person has with them.

Social Skills and Vocational Training

Skills erode during acute episodes. A patient who was holding a job six months ago and had friends two years ago can come back from a hospitalization and find that the conversational rhythm, the workplace reflexes, and the social scaffolding are all gone. Not permanently. Just not where they left them.

Structured social skills training is what it sounds like: deliberate practice. Starting conversations. Reading a room at work. Managing conflict without escalation. Re-entering relationships that went quiet during the acute phase. Supported employment programs pair these skills with real job coaching, and the evidence is that they help people get and keep work when traditional vocational rehabilitation has not.

Cognitive Remediation

Hallucinations and mood can stabilize while the harder, quieter symptoms persist: forgetting appointments, losing the thread of a conversation, struggling to plan a week. These are the symptoms that sit between "stable" and "back to a life I recognize." For many patients, they are what actually prevents the return to work or school.

Cognitive remediation is structured training for those skills. Memory exercises. Attention work. Executive function practice. The programs are not new, but they are one of the most underprescribed interventions in this space. They will not cure cognitive symptoms, but they can meaningfully improve day-to-day function.

The Role of Family and Community Support

No one recovers from schizophrenia alone. That is not a sentimental claim, but a finding that has been reproduced in study after study over several decades.

Family psychoeducation is one of the most consistently supported non-medication interventions in the books. The idea is simple: when the people a patient lives with understand what schizophrenia is, what the medications do, and how to communicate in hard moments, relapse rates drop. A concept in the research called "expressed emotion" describes a household climate marked by high levels of criticism, hostility, or emotional over-involvement. When that climate softens, relapse rates soften with it. Nothing about this says families cause schizophrenia. They don't. But the environment in which treatment either catches or slips is incredibly important.

Community reintegration carries the same weight. A stable apartment. A part-time job, even a small one. Peer support groups. A faith community if that fits. Friendships that survive the acute phase. These are not "lifestyle" factors that sit outside treatment. They are the treatment. A patient with housing and a routine has a very different clinical trajectory from the same patient without them.

How to Choose Among Schizophrenia Treatment Options

The question families ask us is almost never "should we get treatment." It is "how do we pick the right place." A few things matter more than the rest in that decision.

Start with the intake. A good assessment is not a form that takes 20 minutes to fill out. It is a conversation that covers psychiatric history, medication history and response, current symptoms, physical health, substance use, the home situation, and what the patient actually wants out of treatment. If the intake is structured as a checklist, the treatment plan will be too.

Ask how the team communicates. Is there a dedicated case manager? Does the psychiatrist read the therapist's notes? Is metabolic monitoring built into the schedule? Is family involvement standard? Are outcomes tracked? These are the questions we built our care model to answer, and a clinic that stumbles on them is worth a second look.

Insist on shared decision-making. A patient is a participant in their treatment, not a recipient of it. A good clinician lays out the trade-offs of each medication in plain language, listens to what the patient wants, and makes decisions alongside them. A clinician who rushes that or waves it off is telling you something.

Frequently Asked Questions

Q: Can schizophrenia be cured?

Not cured in the traditional sense. Schizophrenia is managed, which is a word that sounds smaller than it is. "Managed" in 2026 can mean living for decades with minimal disruption, working, keeping relationships, and needing medical care the way a person with diabetes does. Functional recovery is achievable for a meaningful number of patients, though not all.

Q: What happens if I stop taking my medication?

The risk of relapse rises sharply. What makes stopping tricky is the delay. Many people who discontinue antipsychotic medication feel fine for weeks, sometimes months, before symptoms return. That gap is long enough to conclude the medication wasn't necessary, and then to be caught off guard when symptoms do come back. Talk to your prescriber before making any changes.

Q: Are there natural treatments for schizophrenia?

Sleep, exercise, nutrition, and stress management support mental health and matter for anyone living with schizophrenia. They are not a substitute for medical treatment. If something is marketed as a "natural cure" for schizophrenia, that is a reason to stop reading. Supplements, herbs, and alternative therapies have not been shown to treat the underlying biology of the condition. Some interact with prescribed medications in ways that can be dangerous.

Q: How do I help a loved one who refuses treatment?

This is the question we hear most from families, and it is the hardest one. A few things help:

  • Anosognosia, a lack of awareness of one's illness, is itself a symptom of schizophrenia. It is not denial. Understanding the difference can change how you approach the conversation.
  • The LEAP method (Listen, Empathize, Agree, Partner), developed by Dr. Xavier Amador, was built for exactly these situations.
  • NAMI's Family-to-Family programs teach communication skills and connect families with others walking the same path.
  • In an acute safety crisis, call 988, the Suicide and Crisis Lifeline, or your local mobile crisis team.

Moving Toward Functional Recovery

A schizophrenia diagnosis is a serious event. It is not a verdict.

The range of schizophrenia treatment options has meaningfully widened since 2024. New medications. New evidence about old medications. Care models with strong outcomes data. Psychosocial interventions that help with the parts of recovery medication cannot touch. The clinical goal has moved from quieting the biology to helping a person live a life they recognize as their own.

What most patients and families need is not a single treatment.

They need a team that treats the whole picture, which means symptoms, physical health, relationships, work, and function, as one problem instead of four.

If you or someone you love is living with schizophrenia, schizoaffective disorder, or a related condition, Amae Health is here to talk. Our care teams include psychiatrists, therapists, primary care providers, dietitians, health coaches, peer mentors, and clinical care coordinators, all working from one shared plan. We see adults 18 and older at our clinics in Los Angeles, Los Altos, San Mateo, Raleigh, New York, and Brooklyn. To start the conversation, request an intake appointment.

‍

Citations

  1. 3 Things to Know About Cobenfy, Yale Medicine. Tier 4 (major academic medical center).
  2. Ostuzzi et al., "Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants," World Psychiatry, 2022. Tier 1 (peer-reviewed).
  3. Kane et al., "Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program," American Journal of Psychiatry, 2016. Tier 1 (peer-reviewed).
  4. NIMH: Team-based Treatment is Better for First Episode Psychosis. Tier 2 (government).

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, 2020. Tier 3 (professional association).

# min read

Bipolar Disorder Supportive Therapy: How It Helps Stabilize Mood

By

Sonia Garcia

|

May 18, 2026

Bipolar disorder changes the weather inside a life. Mood swings disrupt work, sleep, relationships, and the sense that next month will look anything like this one. The emotional exhaustion of cycling through episodes and the strain those episodes put on close relationships are part of why so many patients describe bipolar disorder as harder to live with than almost any other condition they know. Medication is usually the foundation of treatment. But medication alone is rarely enough. Bipolar disorder supportive therapy is one of several psychotherapy approaches that sit alongside medication to turn stability into an actual life.

‍

This guide explains what supportive therapy is, how it fits alongside other therapies, and what kind of help may improve day-to-day stability.

What Is Supportive Therapy For Bipolar Disorder?

Supportive therapy is a psychotherapy approach built around emotional support, trust, validation, and practical coping. It does not focus on deep analysis of the unconscious, and it is not a structured skills protocol. It is the kind of therapy where a clinician listens carefully, helps you make sense of what you are feeling and going through, reinforces what is working, and helps you solve the next problem in front of you.

‍

Supportive therapy is almost always part of a broader treatment plan for bipolar disorder, not a replacement for psychiatric care. Most people combine it with medication management, and many eventually layer in more structured approaches like CBT or family-focused therapy.

What Techniques Are Used in Bipolar Disorder Supportive Therapy

The practical tools a supportive therapist uses include:

‍

  • Emotional validation that acknowledges the real weight of what the person is experiencing
  • Active listening that slows down and surfaces what is actually going on, not just the surface complaint
  • Psychoeducation about the illness cycle, warning signs, and what to expect
  • Problem-solving on concrete day-to-day stressors, from a difficult conversation to a medication side effect
  • Strengthening insight about mood patterns and personal triggers
  • Reinforcing engagement in the full treatment plan, including appointments and medication

How Supportive Therapy Helps People With Bipolar Disorder

Emotional Support During Mood Instability

Mood episodes are disorienting. A depressive stretch can last weeks, a hypomanic period can feel like the most productive month of your life until it crashes, and a mixed episode can fold both into the same week. Supportive therapy gives a person somewhere to bring that weight, week after week, with someone who understands what bipolar disorder looks like from the inside. That consistency alone steadies many patients through the worst stretches.

Building Coping Skills And Daily Stability

The practical work of staying well with bipolar disorder is mostly about routines. Supportive therapy helps people build and protect them:

‍

  • Consistent sleep and wake times, because sleep disruption is a common trigger
  • Strategies for stress management when life gets loud
  • Conflict management skills for relationships under strain
  • Recognizing early warning signs of an episode so they can be interrupted

Supporting Medication Adherence And Ongoing Care

Medication is the foundation of bipolar treatment. But it can also be hard to stay on. Side effects, the feeling of missing hypomanic energy, the belief that symptoms will not return, and plain forgetfulness all contribute to the high discontinuation rates that research keeps finding. Supportive therapy gives people a place to talk honestly about their fears and frustrations with medication, think through side effects with a trusted clinician, and stay engaged when the usual instinct would be to drop out.

Supportive Therapy vs. Other Therapy Approaches

Supportive therapy is one of several psychotherapy approaches with evidence for bipolar disorder. A quick comparison:

Therapy Primary focus Typical use in bipolar disorder
Supportive therapy Emotional support, coping, engagement Early in treatment, during stabilization, alongside medication
Cognitive behavioral therapy (CBT) Identifying and reshaping unhelpful thought patterns Managing depressive episodes, relapse prevention
Dialectical behavior therapy (DBT) Emotion regulation, distress tolerance, interpersonal skills High emotional reactivity, self-harm risk, co-occurring BPD
Family-focused therapy (FFT) Communication and relapse planning with family Adolescents and adults with close family involvement
Interpersonal and social rhythm therapy (IPSRT) Stabilizing sleep, routines, and interpersonal patterns Rhythm disruption, relationship stressors, mood cycling

A large systematic review of 39 randomized trials of adjunctive psychotherapy for bipolar disorder found that family-focused, cognitive behavioral, and psychoeducational therapies reduced episode recurrence compared with usual treatment (Miklowitz et al., JAMA Psychiatry, 2021).

When Other Therapies May Be Added

Supportive therapy is often the right starting point, especially after a new diagnosis or during stabilization. Over time, many patients add a more structured approach:

‍

  • CBT for persistent depressive symptoms or to build relapse-prevention skills
  • DBT for patients with heavy emotional reactivity or co-occurring BPD features
  • IPSRT for people whose episodes are tied to disrupted sleep and routines
  • Family-focused therapy when relationship dynamics are shaping the illness course

‍

The choice depends on symptoms, goals, and what the person actually needs at that stage. A skilled clinician will adjust the approach as the picture changes.

What To Expect In Bipolar Disorder Supportive Therapy

Sessions are usually 45 to 50 minutes and are typically weekly at the start. The work is conversational rather than homework-driven. A session might open with what happened that week, look at mood patterns since the last visit, surface any new stressors, and end with a small plan for the week ahead.

‍

The clinician will pay attention to warning signs: sleep changes, energy shifts, spending or relationship patterns, and medication side effects. Over time, a person in supportive therapy often becomes much better at tracking their own mood, which makes the intervals between episodes longer and the episodes themselves shorter.

Who May Benefit Most

Supportive therapy tends to help most for:

‍

  • People newly diagnosed who need to make sense of what bipolar disorder is and what the next year can look like
  • People adjusting to treatment who are figuring out medication, routines, and how to communicate about the illness
  • People navigating the emotional fallout of a recent episode, including shame, regret, or strain with family
  • People in long-term stabilization who want a steady clinician presence without intensive protocols

‍

It is less of a match for patients who need heavy skills training for severe emotion dysregulation or those in active crisis, where higher levels of care are indicated.

When To Seek Professional Help For Bipolar Disorder

A few questions to ask yourself:

‍

  • Are mood episodes interfering with work, school, or close relationships?
  • Has your sleep pattern changed significantly for more than a week?
  • Are you making impulsive decisions that later feel hard to explain?
  • Is someone close to you saying your behavior feels out of character?
  • Are you having thoughts of self-harm or suicide?

‍

If the answer to any of these is yes, it is worth calling a clinician. For immediate safety concerns, call 988 for the Suicide and Crisis Lifeline.

Bipolar Disorder Care At Amae Health

At Amae Health, we support individuals battling bipolar disorder. Our approach is integrated: psychiatrists, therapists, primary care providers, dietitians, health coaches, peer mentors, and clinical care coordinators all work from one shared treatment plan. That structure matters for bipolar disorder, because the condition touches sleep, physical health, medication, and relationships at the same time, and fragmented care usually misses something.

‍

If bipolar symptoms are disrupting daily life for you or someone you love, we can help with evaluation, treatment planning, and ongoing support. Learn more about our bipolar disorder care, read our guide to the most effective treatments for bipolar disorder, or call 1-888-860-2825 to start the conversation.

‍

Citations

  1. Miklowitz et al., "Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis," JAMA Psychiatry, 2021. Tier 1 (peer-reviewed).

‍

# min read

TMS vs Ketamine and Spravato for Treatment-Resistant Depression

By

Sonia Garcia

|

October 5, 2026

If you are comparing TMS, ketamine, and Spravato for depression, you have probably reached the point where standard antidepressants have not done enough. All three are evidence-based options for treatment-resistant depression, and beyond that they have little in common. TMS is a course of magnetic stimulation delivered while you sit awake in a chair. Ketamine is an anesthetic given by IV, used off-label for depression. Spravato is a nasal spray made from esketamine, one of the two mirror-image forms that make up ketamine, with its own FDA approval and its own rulebook.

‍

None of the three is universally better. They differ in mechanism, speed, setting, and monitoring, and the right one depends on your clinical history and how you respond. Treatment-resistant depression generally means depression that has not adequately improved after at least two antidepressants taken at a proper dose for long enough, and that is the group where all three are most often used.

What Is TMS?

Transcranial magnetic stimulation uses a coil placed against the scalp to deliver focused magnetic pulses to the left dorsolateral prefrontal cortex, a region involved in mood regulation. The FDA first cleared TMS for major depressive disorder in 2008, according to the National Institute of Mental Health. It is delivered in an office, with no anesthesia and no medication.

‍

Our standard TMS course runs 20 to 30 daily sessions over four to six weeks, each 30 to 40 minutes long. You stay awake throughout and drive yourself home afterward. In real-world outcome data from 42 U.S. practices, more than half of patients with medication-resistant depression responded to a standard course, and more than a third reached remission.

What Is Ketamine Therapy?

Ketamine has been an FDA-approved anesthetic since 1970. Its use for depression is off-label: prescribed for a purpose the FDA has not formally approved, which is legal and common in medicine but leaves the safeguards less standardized. It is usually given as an IV infusion in a monitored clinic, as a series of sessions over a few weeks.

‍

Ketamine blocks the NMDA receptor, a glutamate receptor, rather than acting on serotonin like standard antidepressants, and that difference is thought to explain its speed. In a landmark 2006 trial, 18 people with treatment-resistant depression received a single infusion of 0.5 mg/kg, and their symptoms improved significantly within 110 minutes. By the next day, 71% had responded and 29% were in remission. One week later, 35% still met the response threshold. Rapid, real, and often short-lived.

‍

The catch is in the monitoring. Ketamine causes dissociation, a sense of detachment from your body or surroundings, plus sedation and blood pressure rises during and after the infusion, so you are observed until those effects pass and cannot drive that day. In a 2017 consensus statement in JAMA Psychiatry, an American Psychiatric Association task force found the evidence for rapid antidepressant effects convincing but the studies small, the longer-term efficacy data lacking, and the safety data on repeated dosing limited.

What Is Spravato (Esketamine)?

Ketamine is a mixture of two mirror-image molecules. Spravato is esketamine, one of those two, delivered as a nasal spray. Unlike IV ketamine, it has FDA approval for depression. The original approval came in March 2019 for treatment-resistant depression alongside an oral antidepressant, a second indication followed for adults with major depressive disorder and acute suicidal thoughts or behavior, and in January 2025 the FDA approved Spravato as a standalone monotherapy for treatment-resistant depression, with no oral antidepressant required, per the current prescribing information.

‍

That approval comes with a rulebook. Spravato can only be given at a setting certified under a Risk Evaluation and Mitigation Strategy (REMS) program: you take the spray under supervision, you are monitored for at least two hours before an assessment clears you to leave, and you cannot drive until the next day after a restful sleep. Its label carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in younger patients.

‍

So is Spravato the same as ketamine? Related, not identical: same molecular family, same receptor, similar rapid onset and dissociative effects, but a different route, a formal FDA indication, and mandatory monitoring rules that off-label ketamine does not carry. For most people comparing TMS vs Spravato, those rules and insurance coverage are the practical differences that matter.

TMS vs Ketamine vs Spravato: Side-by-Side Comparison

Feature TMS IV ketamine Spravato (esketamine)
Mechanism Magnetic pulses stimulate the prefrontal cortex NMDA receptor antagonist, given intravenously NMDA receptor antagonist, nasal spray
FDA status Cleared for MDD (2008) and OCD (2018) Approved as an anesthetic; off-label for depression Approved for TRD (2019 with an oral antidepressant; 2025 as monotherapy) and for MDD with acute suicidal ideation
Onset Gradual, across a multi-week course Hours to days Hours to days
Session format 30 to 40 minutes, awake, in an office Infusion in a monitored clinic Self-administered spray under supervision in a certified setting
Monitoring None after the session Observed during and after the infusion At least two hours after each dose
Driving Drive yourself home Not that day Not until the next day
Typical course 20 to 30 daily sessions over 4 to 6 weeks A series of infusions over several weeks, then maintenance as needed Twice a week for the first four weeks, then weekly, with later dosing individualized
Common side effects Scalp discomfort, headache Dissociation, sedation, blood pressure rise, nausea Dissociation, dizziness, nausea, sedation, vertigo, raised blood pressure

Onset and Duration of Effect

Speed is the clearest dividing line. TMS builds gradually, and many people do not notice a clear change until the second or third week or later. Ketamine and Spravato can shift symptoms within hours to days.

‍

Speed and staying power are different things. Ketamine's effect after a single infusion often fades within a week or two, which is why it is given as a series with maintenance dosing. Spravato starts at twice a week and tapers, with the need for continued treatment reassessed along the way. Research on durability is still developing for all three, and none should be described as permanent.

Side Effects and Safety Considerations

TMS side effects are local and short-lived: scalp discomfort where the coil sits, headache, and sometimes brief lightheadedness or facial muscle twitching during the pulses. These usually settle within the first week, and because nothing enters the bloodstream there is no weight gain, sexual dysfunction, or sedation. Seizure is the one serious risk, exceedingly rare, and TMS is not used in people with a seizure history, metal in the head, or implanted electronic devices.

‍

Ketamine and Spravato share a different profile. The most common reactions to Spravato in trials were dissociation, dizziness, nausea, sedation, vertigo, numbness, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache. Those effects peak in the hours after dosing, which is what the monitoring window is for, and both drugs carry a potential for misuse that shapes who is a candidate. Each option has its own screening, and a contraindication to one does not rule out the others.

Cost and Insurance

For TMS, most commercial insurers cover treatment for major depressive disorder once eligibility criteria are met, typically a confirmed diagnosis and documented antidepressant trials without adequate relief. Prior authorization is standard. For TMS we take all commercial insurance plans, cash pay is available, and authorization is something our intake team manages for you.

‍

Spravato is more commonly covered than off-label ketamine because it has an FDA indication insurers can write criteria around, though prior authorization and documentation of failed antidepressant trials are typically required. Ketamine infusion coverage varies widely, and many clinics are self-pay. Published cost estimates vary so much by dose, frequency, and insurance status that a single dollar figure would mislead; ask each provider and your insurer directly.

Can These Treatments Be Combined?

Sometimes, and the research is early. A 2024 systematic review found six published studies on combining TMS with ketamine, mostly case reports plus one retrospective review and one small pilot, and reported substantial and sustained improvement with generally mild side effects. The authors also said the designs were too varied and the samples too small for firm conclusions, and called for randomized trials.

‍

In practice, TMS and Spravato are sometimes used one after the other. Combining any of these is a clinical judgment a psychiatrist makes from your history, not a general recommendation, and the more common pattern is to use one, assess the response, then decide.

Choosing Between Them: What Influences the Decision

A psychiatrist weighing these options usually works through a short list:

‍

  • Treatment history. Which antidepressants, at what doses, for how long, and whether psychotherapy has been tried.
  • How urgently relief is needed. When symptoms are severe or suicidal thoughts are present, a faster-acting option may take priority, alongside care for suicidal thoughts.
  • Tolerance for the experience. Dissociation and a two-hour monitored window, versus a daily half-hour appointment for several weeks with no drug effects.
  • Practical constraints. Whether you can get to daily sessions, whether someone can drive you home after Spravato or ketamine, and what your insurance will authorize.
  • Health factors. Seizure history, metal implants, blood pressure, and any history of substance misuse each rule options in or out.
  • What else is in place. Any of the three works better inside ongoing psychiatric care and therapy than as a standalone fix.

Making the Decision With an Integrated Care Team

TMS, ketamine, and Spravato are tools, and tools do their best work inside a plan: a psychiatrist who knows your history, a therapist working alongside the biological treatment, and a team that notices when the plan needs to change.

‍

That is how we work. At Amae, our one-team care model combines psychiatry, therapy, primary care, and peer support, and TMS and Spravato are available through our Los Angeles and Bay Area clinics as part of that care. If you have been through the antidepressant cycle and want a clear, unhurried look at what comes next, talk with an Amae psychiatrist about your options. If you are in crisis or thinking about suicide, call or text 988 now.

Frequently Asked Questions

What is the difference between TMS and ketamine for depression?

TMS stimulates the brain with magnetic pulses over a course of daily outpatient sessions, with no drug, no sedation, and no monitoring afterward. Ketamine is a medication that acts on NMDA receptors, given by infusion or, as esketamine, by nasal spray, with monitored sedation and dissociation and often faster but shorter-lived effects.

Is Spravato the same as ketamine?

Related but not identical. Spravato is esketamine, the S-enantiomer of the ketamine molecule, delivered as an FDA-approved nasal spray under a required monitoring program. Ketamine infusions use the full ketamine compound and are prescribed off-label for depression, without an FDA indication for that use.

Is Spravato only approved with an antidepressant?

Not anymore. The original 2019 approval was for use alongside an oral antidepressant, and in January 2025 the FDA also approved Spravato as a standalone monotherapy for adults with treatment-resistant depression. Whether it is used alone or with an antidepressant is a decision your psychiatrist makes based on your situation.

Which works faster, TMS or Spravato?

Spravato. Esketamine and ketamine can produce symptom change within hours to days, while TMS builds gradually across a four-to-six-week course. Faster onset does not mean more durable improvement, and both durability and side effects belong in the comparison.

Can TMS and Spravato be used together?

Sometimes, as a clinical decision made with a psychiatrist based on your individual history. Both can be part of a broader treatment-resistant depression plan alongside medication and therapy, and the evidence on combining them is still early.

Is ketamine or Spravato covered by insurance?

Spravato is more commonly covered, because it has an FDA indication insurers can build criteria around, though prior authorization and proof of failed antidepressant trials are usually required. Coverage for off-label ketamine infusions varies widely and is often self-pay. Confirm with the provider and your insurer before starting.

‍

Citations

  1. National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies
  2. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. 2012. https://pubmed.ncbi.nlm.nih.gov/22689344/
  3. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006. https://pubmed.ncbi.nlm.nih.gov/16894061/
  4. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017. https://pubmed.ncbi.nlm.nih.gov/28249076/
  5. U.S. Food and Drug Administration. Drugs@FDA: SPRAVATO (esketamine), NDA 211243, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243
  6. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
  7. Arubuolawe OO, Folorunsho IL, Busari AK, et al. Combination of transcranial magnetic stimulation and ketamine in treatment-resistant depression: a systematic review. Cureus. 2024. https://pubmed.ncbi.nlm.nih.gov/39156335/
  8. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍